Dr. Umar Farooq, MD
Hematology & Oncology (Hematology & Oncology Physician)
200 Hawkins Dr, Department Of Internal Medicine
Iowa City, IA 52242
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 178
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IA license MD-41505
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- University of Iowa Health Care Medical Center Down Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 178
- Services billed
- 838
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 409 | 121 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 139 | 31 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 43 | 18 |
| Hospital discharge day management, more than 30 minutes | 19 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Iowa City, IA | 99 |
| Prednisone Other prescribers in Iowa City, IA | 62 |
| Ondansetron Hcl Other prescribers in Iowa City, IA | 48 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Iowa City, IA | 42 |
| Prochlorperazine Maleate Other prescribers in Iowa City, IA | 39 |
| Eliquis (apixaban) Other prescribers in Iowa City, IA | 32 |
| Gabapentin Other prescribers in Iowa City, IA | 26 |
| Allopurinol Other prescribers in Iowa City, IA | 24 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Iowa City, IA | 20 |
| Venclexta (venetoclax) | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 11 payments worth $10,975 in total to this clinician.
| Kite Pharma, Inc. | $10,866 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $108 |
| Consulting Fee | $9,470 |
|---|---|
| Travel and Lodging | $1,010 |
| Food and Beverage | $495 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099453;GTF;10416680 | $9,470 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099805;GTF;10416680 | $583 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099177;GTF;10416680 | $427 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $667,612 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC - A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.
Genmab U.S., Inc. - A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03888105 - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT03681561 - A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.